Neoleukin Therapeutics, Inc. – NASDAQ:NLTX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Neoleukin Therapeutics stock price monthly change
+4.18%
month
Neoleukin Therapeutics stock price quarterly change
+353.25%
quarter
Neoleukin Therapeutics stock price yearly change
+671.10%
year
Neoleukin Therapeutics key metrics
Market Cap | 8.19M |
Enterprise value | 17.25M |
P/E | -0.75 |
EV/Sales | N/A |
EV/EBITDA | -0.32 |
Price/Sales | N/A |
Price/Book | 0.45 |
PEG ratio | -0.13 |
EPS | -2.64 |
Revenue | N/A |
EBITDA | -29.17M |
Income | -39.35M |
Revenue Q/Q | N/A |
Revenue Y/Y | -100% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNeoleukin Therapeutics stock price history
Neoleukin Therapeutics stock forecast
Neoleukin Therapeutics financial statements
| Dec 2022 | 0 | -12.63M | |
|---|---|---|---|
| Mar 2023 | 0 | -20.10M | |
| Jun 2023 | 0 | -2.08M | |
| Sep 2023 | 0 | -4.52M |
| 2025 | 0 | -200.17M |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-03-20 | -0.30317 | -0.24 |
|---|
| Dec 2022 | 115948000 | 21.61M | 18.64% |
|---|---|---|---|
| Mar 2023 | 98460000 | 17.10M | 17.37% |
| Jun 2023 | 94005000 | 14.42M | 15.35% |
| Sep 2023 | 89586000 | 14.35M | 16.02% |
| Dec 2022 | -10.93M | 8.46M | 18K |
|---|---|---|---|
| Mar 2023 | -13.03M | 10.70M | -66K |
| Jun 2023 | -4.04M | -411K | -294K |
| Sep 2023 | -4.26M | -1.61M | -1K |
Neoleukin Therapeutics alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Neoleukin Therapeutics other data
5.43%
-25.40%
of NLTX is owned by hedge funds
18
-28
2.99M
-14.03M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 0 | 17696 |
| Apr 2023 | 0 | 3769 |
| Aug 2023 | 2285342 | 1323 |
| Quarter | Transcript |
|---|---|
| Q2 2022 10 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q4 2021 1 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q4 2020 25 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Q2 2020 12 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Jonathan G. Drachman (1962) Chief Executive Officer, Pres & Director | $638,430 |
| Mr. Robert Ho (1976) Chief Financial Officer | $472,290 |
-
When is Neoleukin Therapeutics's next earnings date?
Unfortunately, Neoleukin Therapeutics's (NLTX) next earnings date is currently unknown.
-
Does Neoleukin Therapeutics pay dividends?
No, Neoleukin Therapeutics does not pay dividends.
-
How much money does Neoleukin Therapeutics make?
Neoleukin Therapeutics has a market capitalization of 8.19M. Neoleukin Therapeutics made a loss 56.02M US dollars in net income (profit) last year or -$0.24 on an earnings per share basis.
-
What is Neoleukin Therapeutics's stock symbol?
Neoleukin Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "NLTX".
-
What is Neoleukin Therapeutics's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Neoleukin Therapeutics?
Shares of Neoleukin Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Neoleukin Therapeutics's key executives?
Neoleukin Therapeutics's management team includes the following people:
- Dr. Jonathan G. Drachman Chief Executive Officer, Pres & Director(age: 63, pay: $638,430)
- Mr. Robert Ho Chief Financial Officer(age: 49, pay: $472,290)
-
How many employees does Neoleukin Therapeutics have?
As Jul 2024, Neoleukin Therapeutics employs 7 workers.
-
When Neoleukin Therapeutics went public?
Neoleukin Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 7 Mar 2014.
-
What is Neoleukin Therapeutics's official website?
The official website for Neoleukin Therapeutics is neoleukin.com.
-
Where are Neoleukin Therapeutics's headquarters?
Neoleukin Therapeutics is headquartered at 188 East Blaine Street, Seattle, WA.
-
How can i contact Neoleukin Therapeutics?
Neoleukin Therapeutics's mailing address is 188 East Blaine Street, Seattle, WA and company can be reached via phone at +855 2266447.
Neoleukin Therapeutics company profile:
Neoleukin Therapeutics, Inc.
neoleukin.comExchange:
NASDAQ
Full time employees:
7
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
188 East Blaine Street
Seattle, WA 98102
Seattle, WA 98102
CIK: 0001404644
ISIN: US64049K2033
CUSIP: 64049K104
